Information Provided By:
Fly News Breaks for June 14, 2016
ROSG
Jun 14, 2016 | 08:30 EDT
Cantor believes that Rosetta's stock was weak yesterday due to confusion about Friday's announcement from CMS. The firm says that reimbursement for the company's Cancer Origin Test will not be affected by CMS' proposed changes, while the company's Reveal Thyroid Classification test also will not be affected by the proposals. Cantor keeps a Speculative Buy rating on Rosetta.
News For ROSG From the Last 2 Days
There are no results for your query ROSG
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.